# Tarsus Pharmaceuticals

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/tarsus-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/tarsus-pharmaceuticals

## Recent coverage (1 stories)

### Tarsus and ORIC FY 2025: Commercial Scaling vs. Clinical Discipline
2026-02-23 22:49:35 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Tarsus Pharmaceuticals outperformed revenue expectations with $151.6M in sales driven by XDEMVY, while ORIC Pharmaceuticals showcased clinical resilience with a narrowed loss and key oncology pipeline updates.
Full story: https://getbiobrief.com/story/tarsus-oric-fy2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.